



The Illinois Medical Bulletin



The Association Between Chronic *Helicobacter pylori* Infection and the Risk of Gastric Cancer: A Review of Evidence

¹A.Blake-Sheehy, ²A. Bogard

^{1,2} University of Illinois College of Medicine

Corresponding Email : blakesheehymd283474@gmail.com

Article History :

Received date : 2012/10/12
Revised date : 2012/11/28
Accepted date : 2012/12/09
Published date : 2013/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: In the early 21st century, gastric cancer remained a significant cause of cancer-related mortality globally. During this period, research focus intensified on the role of infectious agents in carcinogenesis, with the bacterium *Helicobacter pylori* emerging as the primary suspect in the etiology of gastric adenocarcinoma. This review synthesises the pivotal scientific literature published that solidified the causal link between chronic *H. pylori* infection and the development of gastric cancer.

Literature Review: Large-scale prospective studies published in this decade provided definitive evidence that chronic *H. pylori* infection was the single most important risk factor for non-cardia gastric cancer. The pathogenic mechanism was elucidated through the Correa cascade, a multi-step pathway of histologic progression from chronic gastritis to atrophy, intestinal metaplasia, dysplasia, and finally carcinoma, with *H. pylori* acting as the principal trigger. Research identified specific bacterial virulence factors, most notably the oncoprotein CagA, that significantly increase cancer risk by disrupting host cell signaling pathways.

Furthermore, landmark intervention trials provided crucial evidence that eradicating the infection could prevent or slow the progression of pre-cancerous lesions, establishing a proof-of-concept for gastric cancer prevention through antimicrobial therapy.

Conclusion: The body of evidence from 2000-2010 transformed the understanding of gastric cancer from an idiopathic disease to an infectious-disease-driven malignancy. *H. pylori* was unequivocally confirmed as the causative agent, paving the way for primary prevention strategies based on its detection and eradication.

Keywords: *Helicobacter pylori*, Gastric Cancer, Gastric Adenocarcinoma, CagA, Correa Cascade.

INTRODUCTION

Gastric cancer, particularly gastric adenocarcinoma, stood as one of the world's deadliest malignancies at the beginning of the 21st century. For decades, its etiology was poorly understood, attributed to a vague combination of dietary and genetic factors. However, this perspective was revolutionised by the study of *Helicobacter pylori*, a spiral-shaped, microaerophilic bacterium uniquely adapted to colonise the harsh acidic environment of the human stomach. While its role in causing peptic ulcer disease was well-established, the period between 2000 and 2010 was critical for cementing its status as the leading cause of gastric cancer.

The recognition of *H. pylori* as a Class I carcinogen by the International Agency for Research on Cancer (IARC) in 1994 set the stage for a decade of intense investigation. This research aimed to move beyond statistical association to establish a clear causal pathway, identify specific mechanisms of carcinogenesis, and explore the potential for cancer prevention. This literature review will synthesise the key publications from the pivotal decade of 2000-2010 that defined the relationship between chronic *H. pylori* infection and the risk of developing gastric cancer.

LITERATURE REVIEW

The evidence linking *H. pylori* to gastric cancer, which solidified between 2000 and 2010, can be examined through its epidemiological confirmation, pathogenic mechanisms, and the impact of therapeutic intervention.

First, the epidemiological evidence became irrefutable during this period. While earlier case-control studies had suggested a link, it was large-scale prospective studies that provided the most compelling proof. A landmark study by Uemura et al. (2001) prospectively followed 1,526 Japanese patients. Over an average follow-up of nearly eight years, gastric cancers developed in 2.9% of the *H. pylori*-infected individuals, whereas not a single case developed in the uninfected group. This provided powerful direct evidence that the infection was a necessary factor for the vast majority of gastric cancers. These findings were supported by numerous other cohort studies and meta-analyses throughout the decade, confirming that the infection conferred a multi-fold increase in the risk of non-cardia gastric adenocarcinoma.

Second, the pathogenic pathway from infection to cancer was clearly defined. The multi-step model of gastric carcinogenesis, known as the Correa cascade, was widely accepted and validated during this time. The model proposes a sequence of histologic changes: normal gastric mucosa -> chronic non-atrophic gastritis -> multifocal atrophic gastritis -> intestinal metaplasia -> dysplasia -> and finally, invasive carcinoma (Correa and Houghton, 2007). Literature from this period established that *H. pylori*-induced chronic inflammation was the essential engine driving this entire cascade. The infection initiates a persistent gastritis which, over decades, leads to the loss of parietal cells and the development of atrophy and intestinal metaplasia—lesions widely recognised as pre-cancerous.

Research also delved into specific bacterial virulence factors that modulate cancer risk. The cytotoxin-associated gene A (CagA) was identified as a critical determinant. Strains of *H. pylori* that possessed the *cag* pathogenicity island were found to be far more strongly associated with gastric cancer. The CagA protein is physically injected into gastric epithelial cells, where it functions as a bacterial oncoprotein, disrupting cell polarity, promoting cell proliferation, and inhibiting apoptosis by interfering with host tumour suppressor proteins (Hatakeyama, 2004; Peek and Blaser, 2002). This provided a direct molecular mechanism for the oncogenic potential of the bacterium.

Finally, this decade saw the publication of crucial intervention trials testing the ultimate question: can eradicating *H. pylori* prevent gastric cancer? A landmark randomised trial in a high-risk Chinese population by Wong et al. (2004) demonstrated that eradication therapy could significantly reduce the incidence of gastric cancer development. The benefit was most pronounced in patients who did not already have pre-cancerous lesions like atrophy or intestinal

metaplasia at baseline, suggesting that there is a "point of no return" after which the damage may be irreversible. This study provided the first major proof-of-principle that gastric cancer is a preventable malignancy.

CONCLUSION

The literature published between 2000 and 2010 was definitive in cementing the causal role of chronic *Helicobacter pylori* infection in the pathogenesis of gastric cancer. The decade provided robust, prospective epidemiological evidence, clarified the step-wise pathogenic cascade driven by chronic inflammation, and identified key bacterial oncoproteins like CagA that directly manipulate host cell biology.

Most significantly, this period yielded critical evidence from intervention trials demonstrating that gastric cancer is, in principle, a preventable disease. The finding that antibiotic-mediated eradication of *H. pylori* could halt the progression to cancer fundamentally altered the clinical and public health approach to this deadly malignancy. The research of this era successfully reframed gastric cancer, transforming it from an enigmatic disease of aging into a well-understood consequence of a chronic bacterial infection, thereby opening the door to targeted prevention strategies.

REFERENCES

- Correa, P. and Houghton, J. (2007) 'Carcinogenesis of *Helicobacter pylori*', *Gastroenterology*, 133(2), pp. 659-672.
- Hatakeyama, M. (2004) 'Oncogenic mechanisms of the *Helicobacter pylori* CagA protein', *Nature Reviews Cancer*, 4(9), pp. 688-694.
- Peek, R.M., Jr. and Blaser, M.J. (2002) '*Helicobacter pylori* and gastrointestinal tract adenocarcinomas', *Nature Reviews Cancer*, 2(1), pp. 28-37.
- Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N. and Schlemper, R.J. (2001) '*Helicobacter pylori* infection and the development of gastric cancer', *New England Journal of Medicine*, 345(11), pp. 784-789.
- Wong, B.C., Lam, S.K., Wong, W.M., Chen, J.S., Zheng, T.T., Feng, R.E., Lai, K.C., Hu, W.H., Yuen, S.T., Leung, S.Y., Fong, D.Y., Ho, J., Ching, C.K. and Chen, J.S. (2004) '*Helicobacter*

pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial', *JAMA*, 291(2), pp. 187-194.